Kidney cancer pathology in the new context of targeted therapy

Pathobiology

Volumn 78, Issue 2, 2011, Pages 90-98

  Allory, Yves ^a,b   Culine, Stéphane ^a,b   De La Taille, Alexandre ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

HIF; mTOR; Renal cell carcinoma; Targeted therapy; VEGF; VHL

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PAZOPANIB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VON HIPPEL LINDAU PROTEIN;

ANTIANGIOGENIC THERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DRUG MEGADOSE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GENES, MYC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79959287950     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000315543     Document Type: Review

References (58)

1. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
2. Motzer RJ, Bander NH, Nanus DM: Renalcell carcinoma. N Engl J Med 1996; 335: 865-875.
3. Eble J, Sauter G, Epstein J, Seesterheen I (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004.
4. Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S: Treatment selection for patients with metastatic renal cell carcinoma. Cancer 2009; 115: 2327-2333.
5. Jones J, Libermann TA: Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res 2007; 13: 685s-692s.
6. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
7. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al: Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-209.
8. Srigley JR, Delahunt B: Uncommon and recently described renal carcinomas. Mod Pathol 2009; 22(suppl 2):S2-S23.
9. Klatte T, Pantuck AJ, Said JW, Seligon DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar F: Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009; 15: 1162-1169.
10. Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R: Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009; 40: 10-29.
11. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, et al: Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009; 15: 7582-7592.
12. Kaelin WG: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13: 680s-684s.
13. Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, et al: Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene 2007; 26: 1346-1350. (Pubitemid 46328469)
14. Beroukhim R, Brunet J, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al: Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69: 4674-4681.
15. Gad S, Lefèvre SH, Khoo SK, Giraud S, Vieillefond A, Vasiliu V, et al: Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 2007; 96: 336-340. (Pubitemid 46160640)
16. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275. (Pubitemid 29246458)
17. Maxwell PH: The HIF pathway in cancer. Semin Cell Dev Biol 2005; 16: 523-530.
18. Smaldone MC, Maranchie JK: Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 2009; 27: 238-245.
19. Kaelin WG: Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009; 115: 2262-2272.
20. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. (Pubitemid 36910021)
21. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, et al: Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178: 1883-1887. (Pubitemid 47538608)
22. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. (Pubitemid 46089672)
23. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318.
24. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, et al: pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 2007; 28: 15-27. (Pubitemid 47531976)
25. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, et al: VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 2009; 11: 994-1001.
26. Choueiri TK, Vaziri SAJ, Jaeger E, Elson P, Wood L, Bhalla IP, et al: von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008; 180: 860-865.
27. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, et al: Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006; 98: 756-762. (Pubitemid 44368020)
28. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung Y, et al: HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143-153. (Pubitemid 41132743)
29. Sudarshan S, Sourbier C, Kong H, Block K, Valera Romero VA, Yang Y, et al: Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29: 4080-4090.
30. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al: Accumulation of Krebs cycle intermediates and overexpression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-2239. (Pubitemid 41418022)
31. Yogev O, Yogev O, Singer E, Shaulian E, Goldberg M, Fox TD, et al: Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol 2010; 8:e1000328.
32. Hudes GR: Targeting mTOR in renal cell carcinoma. Cancer 2009; 115: 2313-2320.
33. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008; 372: 449-456.
34. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, et al: Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25: 3958-3964. (Pubitemid 47477274)
35. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
36. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007; 109: 2257-2267. (Pubitemid 46801555)
37. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 379-385. (Pubitemid 47584475)
38. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, et al: Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009; 115: 3651-3660.
39. Toschi A, Lee E, Gadir N, Ohh M, Foster DA: Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008; 283: 34495-34499.
40. Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, et al: Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One 2008; 3:e3581.
41. Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, et al: The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene 2009; 28: 1594-1604.
42. Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, et al: Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 2009; 106: 18722-18727.
43. Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, et al: Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin. J Med Genet 2010; 47: 182-189.
44. Yamaguchi S, Yoshihiro S, Matsuyama H, Nagao K, Fukunaga K, Matsumoto H, et al: The allelic loss of chromosome 3p25 with cmyc gain is related to the development of clear-cell renal cell carcinoma. Clin Genet 2003; 63: 184-191. (Pubitemid 36949918)
45. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14: 435-446.
46. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, et al: Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007; 67: 3171-3176. (Pubitemid 46724854)
47. Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al: Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 2004; 172: 1256-1261. (Pubitemid 39249692)
48. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, et al: Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009; 15: 1162-1169.
49. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, et al: c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008; 283: 2675-2683.
50. Goldschneider D, Mehlen P: Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010; 29: 1865-1882.
51. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, et al: Kinase requirements in human cells. 3. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 2008; 105: 16484-16489.
52. Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, et al: Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J 2010; 24: 2680-2688. DOI: 10.1096/fj.09-146928.
53. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6:S55-S57.
54. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. (Pubitemid 41702632)
55. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-3721. (Pubitemid 40685588)
56. Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, et al: Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol 2008 ;179: 730-736.
57. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540. (Pubitemid 29368255)
58. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841. (Pubitemid 46224183)